BLAINJECTIONINJECTABLE
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
63
Intelligence
6/8 — Comprehensive
SARCLISA (isatuximab) by Sanofi is cd38-directed antibody interactions [moa]. Approved for cd38-directed cytolytic antibody [epc]. First approved in 2020.
Mechanism of Action
CD38-directed Antibody Interactions
Pharmacologic Class:
CD38-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (63)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Started Oct 2025
40 enrolled
Multiple MyelomaPlasma Cell Leukemia
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Started Jun 2025
63 enrolled
Smouldering Myeloma
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Started Mar 2025
64 enrolled
Plasma Cell Myeloma Refractory
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Started Oct 2024
40 enrolled
T-ALL
Worked on SARCLISA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.